AEGiS-IRIN: UGANDA: Hopes raised over development of cheaper AIDS drug

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

UGANDA: Hopes raised over development of cheaper AIDS drug

Integrated Regional Information Networks - July 16, 1999

NAIROBI, 16 July (IRIN) - A cheaper and more effective drug that reduces the rate of HIV transmission from mother to child by 50 per cent has been developed by Ugandan and American scientists, Ugandan radio reported. The drug, nevirapine (NVP), costs about US $3, unlike the existing drug AZT that requires about US $800. The æLos Angeles Times' quoted Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases which funded the study, as saying the scientists had hoped nevirapine would be at least as good as AZT. But, "it was much better", he said.

The UNAIDS programme in Nairobi confirmed that nevirapine is "relatively cheaper" and "does not need to be taken frequently". UNAIDS Regional Coordinator Warren Namara told IRIN the drug has been in trials for quite a while and it appears "promising".

Uganda's Health Minister Crispus Kiyonga said the research provided real hope that many of Africa's future generations could be protected from the AIDS pandemic.

US Vice President Al Gore expressed great satisfaction over a "promising new treatment" which he said was "at least 70 times lower in cost than a short course of AZT and 200 times less expensive than a long course - and easier to administer".

"This treatment, to help reduce the likelihood of a mother passing along HIV to her child during pregnancy or delivery, is a critical new weapon in the ongoing battle against HIV/AIDS," he said in a statement. "With this treatment, millions of children can start life free from this deadly disease."

"I believe that we must address the growing crisis of HIV/AIDS in this nation, in Africa and around the world. Each and every hour, another 16,000 persons are infected with HIV worldwide, most in the poorest nations," he added.

990716
IR990702

Copyright © 1999 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980 – 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .